Creative Planning cut its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 38.8% during the first quarter, HoldingsChannel.com reports. The firm owned 38,692 shares of the biopharmaceutical company’s stock after selling 24,500 shares during the quarter. Creative Planning’s holdings in Halozyme Therapeutics were worth $623,000 at the end of the most recent quarter.
Other hedge funds have also recently modified their holdings of the company. Bank of Montreal Can raised its stake in Halozyme Therapeutics by 80.4% during the fourth quarter. Bank of Montreal Can now owns 2,011 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 896 shares during the period. Sageworth Trust Co raised its stake in shares of Halozyme Therapeutics by 4,200.0% in the 1st quarter. Sageworth Trust Co now owns 2,150 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 2,100 shares during the period. Amundi Pioneer Asset Management Inc. purchased a new stake in shares of Halozyme Therapeutics in the 4th quarter valued at approximately $140,000. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Halozyme Therapeutics by 33.0% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,791 shares of the biopharmaceutical company’s stock valued at $143,000 after acquiring an additional 2,430 shares during the period. Finally, Pathlight Investors LLC purchased a new stake in shares of Halozyme Therapeutics in the 4th quarter valued at approximately $151,000. 83.32% of the stock is currently owned by institutional investors.
A number of equities research analysts have recently issued reports on the stock. Zacks Investment Research downgraded shares of Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, January 11th. BidaskClub downgraded shares of Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, March 6th. ValuEngine downgraded shares of Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, March 6th. TheStreet downgraded shares of Halozyme Therapeutics from a “c” rating to a “d” rating in a research note on Tuesday, March 5th. Finally, Cantor Fitzgerald set a $24.00 price target on shares of Halozyme Therapeutics and gave the company a “buy” rating in a research note on Thursday, February 28th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $20.17.
Halozyme Therapeutics stock opened at $17.23 on Tuesday. Halozyme Therapeutics, Inc. has a 1 year low of $13.24 and a 1 year high of $20.54. The company has a market capitalization of $2.48 billion, a PE ratio of -30.77 and a beta of 1.79. The company has a current ratio of 2.86, a quick ratio of 2.71 and a debt-to-equity ratio of 0.14.
Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Thursday, February 21st. The biopharmaceutical company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.02. Halozyme Therapeutics had a negative net margin of 52.90% and a negative return on equity of 31.86%. The firm had revenue of $60.23 million for the quarter, compared to the consensus estimate of $59.77 million. During the same period in the prior year, the firm earned $0.85 EPS. The firm’s revenue for the quarter was down 68.2% on a year-over-year basis. On average, research analysts forecast that Halozyme Therapeutics, Inc. will post -0.43 EPS for the current year.
TRADEMARK VIOLATION WARNING: This article was first reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this article on another site, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The correct version of this article can be viewed at https://www.thelincolnianonline.com/2019/05/07/creative-planning-has-623000-holdings-in-halozyme-therapeutics-inc-halo.html.
Halozyme Therapeutics Profile
There is no company description available for Halozyme Therapeutics Inc
Recommended Story: Find a Trading Strategy That Works
Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO).
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.